Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Clinical Trials

Background:

• Chronic refractory angina is a debilitating condition often unresponsive to conventional treatments.
• Intramyocardial human CD34+ cell therapy has shown potential for symptom relief and improved outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of human CD34+ cell therapy versus placebo in patients with chronic refractory angina through a meta-analysis of randomized controlled trials.

Main Methods:

• A meta-analysis of three randomized controlled trials involving 269 patients (179 treated with CD34+ cells, 90 with placebo).
• Doses of CD34+ cells ranged from 5x10^4 to 5x10^5 cells/kg, with follow-up periods of 6 to 24 months.
• Primary outcomes included angina frequency, exercise time, and major adverse cardiovascular events (myocardial infarction, stroke, death).

Main Results:

• CD34+ cell therapy significantly reduced the risk of all-cause mortality (OR 0.24, p=0.01).
• Patients receiving CD34+ cells experienced reduced angina frequency (mean difference -2.91, p=0.0006) and improved exercise time (mean difference 58.62s, p=0.02).
• No significant differences were observed in the rates of myocardial infarction or stroke between the CD34+ cell and placebo groups.

Conclusions:

• Intramyocardial CD34+ cell therapy is superior to placebo for improving mortality, angina frequency, and exercise time in chronic refractory angina.
• The therapy did not significantly increase adverse cardiovascular events, supporting its potential for treating ischemic heart disease.
• Further clinical trials are warranted to confirm these findings and optimize CD34+ cell therapy protocols.